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Abstract In the past decade, we have gained considerable 
insight into the identities of various cytoplasmic signal transduc-
tion cascades and the manner in which they operate in response to 
changes in the extracellular environment. Moreover, we have 
begun to understand what the key players are in cell-cycle 
regulation and how they, in turn, function to promote cell 
division. A long-standing question, however, has been how 
communication between signalling routes and the cell-cycle 
machinery occurs. This review highlights some recent observa-
tions that provide possible links between signal transduction and 
the cell-cycle machinery. 
© 1997 Federation of European Biochemical Societies. 
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1. Rb and regulation of cell proliferation 
An important property of untransformed, eukaryotic cells is 
their ability to respond to changes in their extracellular envi-
ronment, i.e. the local concentration of various factors. These 
factors include mitogens and anti-mitogens, survival factors, 
differentiation-inducing factors and cell-cell and cell-substra-
tum interactions. This variety of signals influences a cell's 
decision to remain (or become) quiescent, to differentiate, to 
undergo programmed cell death or to enter a cell division 
cycle and reproduce. In most cases, a cell is responsive to 
this kind of regulation only in two cell-cycle phases: in quies-
cence (GO) or in Gl , the first gap phase of the cell cycle 
[reviewed in [1]]. During this time window, extracellular sig-
nals are transmitted through cytoplasmic signal cascades 
which, in turn, induce nuclear processes that eventually deter-
mine the type of cellular response. Once a cell has passed a 
specific point in late Gl , termed the restriction point R, it 
becomes largely refractory to proliferation-stimulating fac-
tors: it commits itself to progress until mitosis, even in the 
presence of growth-restraining signals like the cytokine TGF|3, 
contact inhibition, DNA damage or protein synthesis inhibi-
tors [[2], reviewed in [3]]. The transition from a serum-depend-
ent state to a serum-independent state therefore represents an 
important event and much effort has been put into identifying 
the components involved in this decision making. 
The product of the retinoblastoma tumor suppressor gene, 
Rb, likely is intimately involved in this process [3]. Its func-
tion is to connect the cell-cycle clock with the transcriptional 
machinery. Its growth-suppressing activity, exerted during 
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early Gl , is relieved by phosphorylation in mid-to-late Gl , 
thus roughly coinciding with passage of the R point. A critical 
role for Rb in regulating S-phase entry is further supported by 
the observation that Rb is sequestered during cellular trans-
formation by various DNA tumor virus oncoproteins [re-
viewed in [4]] and that the Rb gene carries mutations and 
deletions in various human tumors [reviewed in [5]]. Together, 
these observations suggest that in normal cells inactivation of 
Rb is an obligatory event during Gl progression and entry 
into S phase, and that in transformed cells absence of func-
tional Rb predisposes to uncontrolled onset of DNA replica-
tion. 
In view of the importance of Rb during G0/G1, one would 
predict that physiologic signals influence proliferation, at least 
in part, by modulating Rb activity. Indeed, TGF(3-induced Gl 
arrest was shown already 7 years ago to correlate with accu-
mulation of the hypophosphorylated, growth-suppressive 
form of Rb [6]. Moreover, the oncoproteins of DNA tumor 
viruses appeared capable of overriding the growth-inhibitory 
action of TGFp, through their Rb-binding domains [7]. An 
interesting question then arose as to how Rb, and in partic-
ular its phosphorylation, is regulated. Answers to this ques-
tion not only provide insight into Rb regulation per se, but 
may also allow identification of a component(s) upstream of 
Rb in a pathway from extracellular signalling to cell-cycle 
control. In this respect, (components of) the Rb kinase(s) 
should, ideally, be responsive to specific proliferation-regulat-
ing signals such as serum factors and TGF|3 and, moreover, 
their activities should be essential for S-phase entry. 
2. Cyclin D and its regulators: intermediates between mitogenic 
signalling and Rb 
One such protein that seems to meet the criteria outlined 
above well is cyclin D. First, expression of D-type cyclins (in 
particular Dl and D2) is highly growth-factor dependent; 
because of the short half-lives of both the mRNA and the 
protein, cyclin D levels decline quickly upon mitogen with-
drawal [reviewed in [8]]. In fact, a characteristic property 
that allowed one way of cyclin D identification is its 'delayed 
early' kinetics during mitogenic stimulation of growth-ar-
rested macrophages or fibroblasts [9,10]. Secondly, cyclin D-
dependent kinases (cdk4 and cdk6) can phosphorylate Rb on 
a number of residues [11,12]. Thirdly, interference with cyclin 
Dl function by microinjection of antibodies or antisense 
DNA prevents serum-stimulated fibroblasts from leaving qui-
escence to enter S phase, when performed before or near the 
Gl/S transition [13,14]. Fourthly, ectopic expression of cyclin 
Dl shortens the progression from G0/G1 to S phase by sev-
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eral hours [13,15] and, in conjunction with a second oncogene, 
even allows for transformation of primary cells [16,17]. Fi-
nally, the cyclin D-cdk4/6 kinase is inactivated by TGFP, 
by various mechanisms [18-20]. It is, in this respect, of note 
that cells in cyclin Dl~/~ mice proliferate relatively normally 
[21], which may be explained in part by a possible redundant 
role for cyclin D2. 
Thus, D-type cyclins fulfil at least some important require-
ments for acting as regulatory subunits of genuine Rb kinases 
on one hand and for connecting mitogenic signalling with the 
regulation of Rb-dependent Gl exit on the other. Therefore, 
they have been proposed to act as growth-factor sensors, 
rather than integral components of the cell-cycle clock, such 
as the (Gl/S-specific) E-type cyclin and (S-phase and mitotic) 
A- and B-type cyclins [8]. If Rb and (one of) its regulator(s) 
cyclin D are true components of a pathway that is used by 
extracellular factors to modulate proliferation, one would pre-
dict that, in turn, regulators of cyclin D activity may represent 
additional components in this pathway. Cyclin D-dependent 
kinase activity is controlled in a complex manner, which may 
not be surprising in view of its importance for cell prolifera-
tion. In addition to careful regulation of cyclin D levels, cyclin 
D-cdk4 kinase activity is controlled by subcellular localiza-
tion [14], (de-)phosphorylation [22], translation [23,24] and 
binding to cdk-inhibitory proteins (CKI) [reviewed in [25-27]]. 
The rapidly expanding group of small CKIs antagonizes 
cyclin D-dependent kinase action through protein-protein in-
teractions. They consist of at least two families: Ink4 proteins 
which specifically inhibit cdk4/6, and Cipl/Kipl proteins, 
which are broad-specificity inhibitors of cyclin-cdks [25-28]. 
Are these inhibitors, in addition to cyclin D, also regulated by 
extracellular factors? For at least three inhibitors the answer 
is yes. For example, mRNA and protein abundance of 
pl5 I n M b , as well as p21C i p l , are induced by TGFP, which likely 
is part of the mechanism by which TGFP arrests cells 
[19,20,29]. Moreover, levels of p27Klpl decrease when cells 
leave a quiescent state; conversely, they rise in response to 
TGFP, cAMP, cell-cell contact and mitogen depletion [30-
32]. In the latter case, p27Klpl appears to be required for 
induction of cell-cycle arrest in response to growth-factor 
withdrawal [32]. By contrast, loss of p27Klpl does not seem 
to lead to reduced sensitivity to TGFP [33]. Thus, during the 
regulation of cell proliferation several extracellular factors 
likely converge on the Rb pathway, in particular cyclin D 
and certain CKIs. 
3. Ras and the Rb pathway 
Which cytoplasmic signal-transduction cascades mediate 
the regulation of the Rb pathway as a function of environ-
mental changes? Small GTPase proteins, like those belonging 
to the Ras family, monitor and regulate a wide variety of 
information flows in eukaryotic cells. Ras proteins play crit-
ical roles in both controlled and uncontrolled cellular prolif-
eration [reviewed in [34]]. Extracellular stimuli like EGF, 
PDGF, NGF and CSF-1 activate receptors with intrinsic ty-
rosine kinase activity which, in turn, leads to an increase in 
the amount of GTP-bound Ras [reviewed in [35]]. Activation 
of Ras is mediated by at least two other proteins, Grb2 and 
SOS, the latter of which is translocated to Ras at the plasma 
membrane upon mitogenic stimulation [36-38]. 
The growth-stimulatory effect of oncogenic Ras has been 
demonstrated by its ability to induce S-phase entry upon mi-
croinjection into quiescent fibroblasts [39]. The requirement 
for the wild-type Ras counterpart has first been shown with 
the help of neutralizing antibodies that prevent quiescent fi-
broblasts from cell-cycle entry by serum or several growth 
factors [40]. Interestingly, Ras activity appears to be required 
at all stages prior to the Gl/S transition, as was suggested first 
by data from Mulcahy et al. [40]. Later, similar observations 
were made with a temperature-sensitive K-Ras mutant [41] 
and with the combined use of antibody microinjection and 
cell-cycle inhibitors [42]. Recently, Ras was shown to be active 
during mid Gl , as judged by a novel assay in which activated 
Ras is isolated from cell extracts by virtue of its affinity for 
the Ras-binding domain of Rafl [43]. 
Is there communication between Ras-dependent signalling 
cascades and the Rb pathway? Studies on TGFP and cAMP 
suggest, at the least, functional correlations. First, in Mink 
lung epithelial cells TGFP-induced Gl arrest parallels both 
an increase in GDP-bound Ras [44] (although conflicting re-
sults have been reported [45]), and a modulation of the Rb 
pathway described above. The induction of Gl arrest can be 
prevented by activated Ras [44,46^18]. TGFP arrests cells in 
late G l ; when anti-Ras antibodies are microinjected just prior 
to the release from TGFP, cells do not enter S phase, under-
scoring the observation that Ras activity is not only required 
for the G0/G1 transition, but also for passage of the Gl/S 
boundary [44]. cAMP, on the other hand, has also been 
shown to inhibit the Ras pathway, specifically the Ras-de-
pendent activation of Rafl [49] and MAP kinase [50], along 
with regulating p27Klpl, as discussed above. 
There are, in addition to the correlations discussed here, 
more examples that suggest a role for Ras as an upstream 
regulator of the Rb pathway. For instance, expression of ac-
tive Ras shortens the Gl interval, which is accompanied by an 
increase in levels of cyclin Dl , but not cyclin E or Cdk4 [51-
55]. However, in the absence of growth factors, Ras cannot 
induce cyclin D-dependent kinase activity, probably due to 
the presence of high levels of p27Klpl, which can be overcome 
only in the presence of plasma factors [55]. Similar observa-
tions are made when resting T-cells are stimulated with anti-
gen and IL2, leading to cyclin synthesis and removal of 
p27Klpl, respectively [56,57]. In addition, in microinjection ex-
periments the adeno virus El A oncoproteins can override the 
requirement for Ras during entry into S phase [58]. Since the 
transforming activity of El A can be attributed to its ability to 
sequester a number of cellular proteins, including Rb, also 
these results are compatible with (yet do not demonstrate) a 
model in which Ras and the Rb pathway communicate with 
one another. 
We have recently obtained direct evidence for this hypoth-
esis [59]. Using both an interfering RasAsn17 mutant [60,61] 
and microinjection of neutralizing Ras antibodies [40,42], we 
observed that inactivation of Ras in cycling fibroblasts and 
myoblasts leads to Gl arrest only in the presence of functional 
Rb. Inactivation of Ras causes a decline in cyclin Dl protein 
levels, accumulation of the hypophosphorylated, growth-sup-
pressive form of Rb and Gl arrest. Upon disruption of Rb 
function, either genetically (in Rb / cells) or biochemically 
(by ectopic expression of D cyclins or a downstream target for 
Rb, the E2F-1 transcription factor) cells lose their ability to 
stop proliferating in response to Ras inactivation. In contrast, 
inactivation of Ras in quiescent cells prevents growth-factor 
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Fig. 1. Schematic representation of communication between extracellular factors and cellular proteins. Extracellular factors modulate the activ-
ities of membrane-bound proteins, including receptor tyrosine kinases (indicated by square, ellipse and circle). These signals are subsequently 
transduced through various cytoplasmic signalling cascades, in part in a Ras-dependent manner. In turn, components of the nuclear cell-cycle 
machinery are influenced, which results in the alteration of the activities of Gl- and Gl/S-specinc cyclin-dependent kinases and their inhibitors 
(CKIs). The relevance of this type of communication can for example be illustrated by the signal transduction from Ras to cyclin D and Rb 
(shaded box): this communication route is important for adequate growth regulation (in particular growth inhibition), for disruption of the cy-
clin D-Rb pathway results in cellular failure to respond to downregulation of Ras activity during Gl. For further details see text. 
induction of both immediate-early gene transcription and GO 
exit in an Rb-independent manner. These results are in keep-
ing with the observation that pl6 Ink4a (an Rb-dependent 
growth inhibitor [62-65]) inhibits S-phase entry induced by 
an activated Ras allele [66]. Moreover, they are consistent 
with the recent demonstration that TGFf5 fails to inhibit the 
proliferation of Rb"/" fibroblasts [67]. In sum, accumulating 
evidence suggests that the Rb pathway may indeed form a 
critical target for various Ras-dependent (anti-)mitogenic sig-
nals. 
4. Ras effectors and the Rb pathway 
The use of dominant negative mutants like RasAsn17 has 
revealed the involvement of Ras in a number of different path-
ways, including those constituted by Rafl/MAP kinase kinase 
(MEK)/MAP kinase/RSK [68,69], PI(3)K [70], Rho/Rac/ 
Cdc42 [71], and, as shown recently, KSR1 ([72] and references 
therein). Which of these Ras effectors feeds into Rb-depend-
ent cell-cycle progression? 
Most of these pathways have been implicated in regulation 
of G0/G1 progression. For example, kinase-deficient mutants 
of Rafl, MEKs and MAPKs can block Ras-induced mitogen-
ic signalling and transformation [73-77], as do dominant-neg-
ative mutants of Rac, Rho and Cdc42 [71,78-80] and deregu-
lated expression of MAP kinase phosphatase [81,82]. 
Consistent with this, the use of Ras effector-loop mutants 
has revealed that, in addition to Rafl, multiple cellular factors 
contribute to the transforming potential of Ras [83]. More-
over, simultaneous stimulation of distinct Ras effector path-
ways, involved in either membrane ruffling or MAP kinase 
activation, are required for Ras-induced DNA synthesis [84]. 
Specific inhibitors of PI(3)K block growth factor- or IL2-
induced DNA synthesis [85-87]. It is, in this respect, not clear 
whether PI(3)K signalling requires Ras function, for conflict-
ing results have been reported on the hierarchy of Ras and 
PI(3)K [70,88,89]. The p70S6K kinase is a PI(3)K effector [90], 
and can be activated independently of Ras [91], and by Rho 
family proteins [92]. Microinjection of polyclonal antibodies 
to p70S6K also prevents Gl progression [93], as does an inhib-
itor of p70S6K, rapamycin [94-97]. Rapamycin prevents resting 
T cells from entering the cell cycle upon IL2 treatment, but 
only when rapamycin is added up to a point in Gl , before Rb 
is phosphorylated [98]. Interestingly, this immunosuppressant 
has also been shown to prevent IL2-induced degradation of 
p27Klpl during T-cell mitogenesis [56,57], the relevance of 
which has been underscored with the use of p27Klpl"/~ fibro-
blasts which show reduced sensitivity to rapamycin-induced 
Gl arrest [99]. Finally, polymerized collagen-induced inhibi-
tion of proliferation of arterial muscle cells has recently been 
shown to correlate with suppression of p70S6K and induction 
of p21Cip l and p27Kipl [100]. Thus, cross-talk between (in part 
Ras-dependent) cytoplasmic cascades and Rb-dependent Gl 
exit may involve signal transducers like PI(3)K and p70S6K on 
one hand and CKIs such as p27Klpl and p21Clp l on the other. 
Yet another, more direct, connection between Ras signal-
ling and cell-cycle control is suggested by the interaction be-
tween Rafl and Cdc25A [101]. Cdc25A dephosphorylates reg-
ulatory threonine and tyrosine residues on cdks [102,103], 
which may be modulated upon interaction of Rafl with 
Cdc25A. Cdc25A and B cooperate in oncogenic transforma-
tion with either oncogenic Ras or genetic loss of Rb [104]. The 
resulting suggestion that, at least in this respect, activation of 
Ras and loss of Rb are functionally equivalent, is in agree-
ment with the observation that inactivation of Rb renders 
cells insensitive to downregulation of Ras activity, as dis-
cussed. The latter result suggests a model in which Ras and 
Rb lie on a common pathway. However, a prediction that Ras 
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activity and Rb deficiency would be interchangeable in trans-
formation cooperation assays in general appears incorrect, as 
becomes clear from the observation that pl6Ink4a~/~ fibro-
blasts can be oncogenically transformed by an activated Ras 
allele alone [105]. This result, in turn, would suggest that Ras 
and Rb are components of cooperating, rather than overlap-
ping, pathways. This apparent inconsistency could perhaps be 
explained by the possibility that the roles of Ras in normal 
versus neoplastic cell proliferation may be only partly over-
lapping. This may, for example, be due to the differences in 
duration of Ras activity (periodic versus constitutive, respec-
tively), something that has been proposed previously to be 
important for differential Ras/MAP kinase-dependent signal-
ling [reviewed in [106]]. 
Ras activity is required as soon as cells leave GO upon 
mitogenic stimulation, up to late Gl . Are the Ras effectors 
during exit from quiescence identical to those during Gl pro-
gression and Gl exit? The answer to this question is not 
known, but some observations can be taken into considera-
tion. On one hand, it has recently been clearly shown that Ras 
is activated in mid-Gl, upon release from either mitotis (in 
HeLa cells) or quiescence (in NIH 3T3 cells) [43]. This is 
consistent with previous findings that Ras activity is necessary 
at least twice during exit from GO and Gl , as described above. 
Probably even more interesting is the observation that the 
second peak of Ras activity does not seem to correlate with 
that of MAP kinase activity, nor with that of She phospho-
rylation and Shc-Grb2 complex formation [43]. These data 
suggest that the activation of Ras during Gl is not mediated 
by a Shc/Grb2-dependent pathway and, in addition, that the 
receiver of the mitogenic signal is not the MAP kinase path-
way. On the other hand and as outlined above, it has been 
shown for various Ras effectors (e.g. Rafl, MAP kinase and 
MEK) that their activities are required for colony outgrowth 
of normal cells and for Ras transformation [73,75,82], 
although in some strains of NIH 3T3 cells, Raf/MAP kin-
ase-dependent pathways do not contribute to Ras transforma-
tion [107]. Thus, at this time it is unclear whether overlapping, 
or rather distinct, Ras-effector pathways are involved in pro-
moting exit from GO and from Gl (see Fig. 1). 
5. Signal transduction and gene expression 
Ultimately, many signals transduced by cytoplasmic protein 
cascades during exit from GO are translated into modulation 
of immediate-early gene expression which, in turn, leads to 
alterations in cell-cycle control. Examples of transcription fac-
tors that are induced upon Ras activation are Jun and Ets-1; 
their activities are important since dominant negative mutant 
forms of either protein block Ras transformation [108-110]. 
In addition, Jun and Fos, but not Myc, rescue a block to 
PDGF-induced DNA synthesis imposed by RasAsn17 [111]. 
This suggests that transcription factors like AP-1 and Ets-1 
link Ras signalling to the transcriptional machinery which, in 
turn, triggers a second wave of gene expression, namely that 
of the delayed-early genes like D-type cyclins. Moreover, these 
results place Ras and Myc in two separate pathways leading 
to DNA synthesis. 
The cyclin D genes obviously are attractive candidates to be 
subjected to transcriptional regulation by immediate-early 
gene products. Numerous laboratories have therefore at-
tempted to unravel the mechanism and identify the transcrip-
tion factors responsible for the delayed-early expression of the 
cyclin D genes in response to mitogens. The cyclin Dl pro-
moter contains several elements, including binding sites for 
AP-1, Ets-2, Myc, and CREB/ATF [52,112]. In addition, it 
has been shown that Ras, p42/44 MAP kinase, p38 HOG/ 
MAP kinase, AP-1 family proteins and Rb can regulate the 
cyclin Dl promoter [51,52,112,113]. Conflicting results have 
been reported on the requirement for protein synthesis for full 
activation of the cyclin D gene [10,114,115]. Together, the 
data suggest that transcriptional elements within the cyclin 
Dl promoter respond to a complex variety of signalling path-
ways and transcription factors. It will, in this respect, be of 
interest to determine whether the transcription factors and 
promoter elements involved in cyclin Dl regulation are the 
same during exit from GO and in cycling cells. 
Recently, a potential transcriptional target for Myc has 
been identified, namely the Cdc25A gene [116]. This gene 
can be activated through Myc-binding elements, while 
Cdc25A expression is required for Myc-induced apoptosis 
[116]. Together with the Rafl-Cdc25A interaction described 
above, these data suggest that Cdc25A is regulated by both 
Ras- and Myc-dependent signalling routes. If Cdc25A, indeed, 
is activated by Ras-Rafl signalling, these observations raise 
the question why Cdc25A cooperates with Ras in transforma-
tion [101,104]. A possible explanation for this would be to 
assume that Ras/Rafl activation of Cdc25A needs to be ac-
companied by (Myc-dependent) induction of Cdc25A levels. 
Another connection between Myc and the cell cycle may be 
provided by observation that Myc can override a p27Klpl-in-
duced growth arrest. The mechanism by which this occurs is 
proposed to involve sequestration of p27Klpl by an as yet un-
identified protein, leading to activation of Gl cyclin-cdks [117]. 
Two other connections between signal transduction and 
transcriptional regulation of a cell-cycle component have 
been suggested. First, ST ATI proteins appear to induce 
p21Clp l transcription through specific binding sites [118]. 
This correlates with induction of Gl arrest in response to 
ionizing radiation, for ST ATI -deficient cells arrest upon radi-
ation only after reintroduction of a STAT1 allele. Secondly, 
the cytokine-responsive transcription factor N F - K B has been 
shown to bind the p300 coactivator which, in turn, binds the 
cyclin E-cdk2 kinase [119]. This results in stimulation of NF-
KB-dependent transcription by p300, but only if cyclin E-as-
sociated kinase activity is prevented by expression of either 
p2jCipi o r a n interfering cdk2 mutant. 
6. Conclusion and perspectives 
In this review, we have discussed a number of observations 
that provide new insight into a long-standing problem: how 
cytoplasmic signal transduction cascades are linked to the 
nuclear cell-cycle machinery. Probably the most far-reaching 
conclusion is that it seems that at least a majority of signalling 
routes seems to control cell proliferation through acting on 
components of the Rb pathway, in particular cyclin D-de-
pendent kinases and their CKIs. For example, the observation 
that cells lacking functional Rb, fail to stop proliferating in 
response to inactivation of Ras suggests that, indeed, there is 
close communication between 'classical' signalling and cell-
cycle pathways. It will, therefore, be challenging to look for 
novel Ras targets that may function specifically during Gl , 
but not GO. In this respect, kinetic studies, as performed by 
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Taylor and Shalloway [43], on potential (Ras) target proteins 
serve as informative and relatively reliable tools in addition to 
the common 'block-and-override' experiments. 
D o all signal transduction routes converge on R b ? Prob-
ably not. This is for example illustrated by the observation 
that Rb-deficient fibroblasts require serum factors, albeit at a 
reduced level, for their proliferation [59,120,121]. This indi-
cates that other pathways, in addition to the R b pathway, 
need to be stimulated simultaneously to ensure cell-cycle pro-
gression. A candidate pathway may be one that regulates the 
activity of the cyclin E-cdk2 kinase. In contrast to cyclin D -
cdk4, inactivation of which leads to cessation of proliferation 
only in the context of functional Rb , disruption of cyclin E 
cdk2 function inhibits proliferation in an Rb-independent 
manner [25,122,123]. As outlined above, this may not be com-
pletely accounted for by the observation that cyclin E appears 
to be a transcriptional target of Rb /E2F [124-128]. Thus, 
al though cyclin E is transcriptionally regulated by Rb/E2F 
(as well as post-transcriptionally, i.e. by CKIs like p27 K l p l ) , 
additional, Rb-independent, signals are required for (full) ac-
tivation of the cyclin E cytokinase, necessary for the onset of 
D N A replication. Finally, another cell-cycle kinase that may 
operate independently of R b is cdk3, since a dominant-nega-
tive cdk3 mutan t can induce G l arrest and inhibit E 2 F tran-
scriptional activity in Rb-independent manners [122,129]. 
In conclusion, al though R b undoubtedly is a key player 
that regulates cell-cycle progression in response to (the major-
ity of) mitogenic signals, Rb-independent pathways may op-
erate in concert with R b to trigger additional events that are 
essential for exiting G l and entering S phase. Therefore, it will 
be of interest to identify not only novel components of G l -
specific (Ras-dependent) signalling routes that regulate R b , 
but also pathways that regulate cell proliferation in parallel 
to the R b pathway. 
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